Natrilix SR

Essential HTN.

1 SR tab/24 hr, preferably in the morning.

Should be taken with food: Swallow whole w/ water, do not chew.

Hypersensitivity to indapamide, or to other sulfonamides. Hypokalaemia. Recent CVA. Severe renal failure. Hepatic encephalopathy or severe impairment of liver function.

Discontinue use if hepatic encephalopathy which can progress to hepatic coma; photosensitivity reactions; choroidal effusion w/ visual field defect, transient myopia, acute angle-closure glaucoma occur. Protect exposed areas to the sun or to artificial UVA. Monitor water & electrolyte (plasma Na, K, Ca, Mg) balance & blood glucose in diabetic patients regularly. Hyponatraemia w/ hypovolaemia may be responsible of dehydration & orthostatic hypotension. Concomitant loss of Cl ions may lead to secondary compensatory metabolic alkalosis. High risk of hypokalaemia in elderly, malnourished &/or polymedicated, cirrhotic patients w/ oedema & ascites, CAD & cardiac failure patients; patients w/ long QT interval whether origin is congenital or iatrogenic. Hypokalaemia may cause muscle disorders & rhabdomyolysis; may favor the onset of Torsades de pointes, which may be fatal. Increased urinary excretion of Mg resulting in hypomagnesaemia. May decrease urinary Ca excretion & slight & transitory rise in plasma Ca. Frank hypercalcaemia may be due to previously unrecognized hyperparathyroidism. W/draw treatment prior to investigation of parathyroid function. Increased tendency to gout attacks in hyperuricemic patients. Hypovolaemia; preexisting renal insufficiency. May cause +ve doping tests in athletes. Prompt medical or surgical treatment may need to be considered if IOP remains uncontrolled. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Avoid use during pregnancy. Not recommended during lactation. Childn & adolescents. Plasma creatinine must be adjusted in elderly in relation to age, wt & gender.

Hypokalaemia; hypersensitivity reactions, maculopapular rashes.

Increased plasma lithium. Increased risk of ventricular arrhythmias w/ Torsades de pointes-inducing drugs eg, class Ia (eg, quinidine, hydroquinidine, disopyramide) & class III (eg, amiodarone, sotalol, dofetilide, ibutilide, bretylium) antiarrhythmics; phenothiazines (eg, chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine), benzamides (eg, amisulpride, sulpiride, sultopride, tiapride), other antipsychotic (eg, pimozide); butyrophenones (eg, droperidol, haloperidol); bepridil, cisapride, diphemanil, erythromycin IV, halofantrine, mizolastine, pentamidine, sparfloxacin, moxifloxacin, vincamine IV, methadone, astemizole, terfenadine. Possible reduction of antihypertensive effect w/ NSAIDs (systemic route) including COX-2 selective inhibitors, high-dose ASA (≥3 g daily). Risk of sudden hypotension &/or acute renal failure w/ ACE inhibitors. Increased risk of hypokalaemia (additive effect) w/ other compd causing hypokalaemia eg, amphotericin B (IV), gluco- & mineralocorticoids (systemic route), tetracosactide, stimulant laxatives. Increased antihypertensive effect w/ baclofen. Hypokalaemia &/or hypomagnesaemia predisposing to toxic effects of digitalis. May increase incidence of hypersensitivity reactions to allopurinol. Hypokalaemia or hyperkalaemia (particularly in patients w/ renal failure or diabetes) w/ K-sparing diuretics eg, amiloride, spironolactone, triamterene. Increased risk of metformin-induced lactic acidosis. Increased risk of acute renal failure w/ large doses of iodinated contrast media. Antihypertensive effect & increased risk of orthostatic hypotension (additive effect) w/ imipramine-like antidepressants, neuroleptics. Risk of hypercalcaemia w/ Ca (salts). Risk of increased plasma creatinine w/ ciclosporin, tacrolimus. Decreased antihypertensive effect w/ corticosteroids, tetracosactide (systemic route).

Diuretics

C03BA11 - indapamide ; Belongs to the class of low-ceiling sulfonamide diuretics.

K